762272-99-1

Upstream product

• 676-58-4 methylmagnesium chloride 
• 762272-95-7 2-[3-(3-bromophenyl)-3-hydroxypropyl]benzoic acid methyl ester 
• 165896-48-0 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid methyl ester 
• 762272-97-9 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 762272-97-9 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 762273-01-8 (S)-1-(3-bromo-phenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propan-1-ol 

Relevant academic research and scientific papers

For the synthesis of montelukast intermediate compound and its preparation method

The invention relates to a pharmaceutical intermediate and a preparation method thereof, and especially relates to an intermediate compound represented by the formula (1) for synthesizing montelukast; wherein in the formula the X' represents a halogen ele

The resolution of important pharmaceutical building blocks by palladium-catalyzed aerobic oxidation of secondary alcohols

The palladium-catalyzed aerobic oxidative kinetic resolution of key pharmaceutical building blocks is described. Substrates investigated are relevant to the enantioselective preparation of Prozac, Singulair, and the promising hNK-1 receptor antagonist from Merck. The latter provides the most selective aerobic oxidative kinetic resolution yet described.